# US 2010/0144828 A1 · Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144828 A1
- Document ID: US20100144828A1
- Status: Published application
- Kind: A1
- Application number: 12/532,763
- Filed: 2008-03-21
- Published: 2010-06-10
- Earliest claimed: 2007-03-23
- Assignees: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutica
- Inventors: Zhanggui Wu; Wei Wei
- Web page: https://patentgrep.com/patent/US20100144828A1

## CPC

- C07C 235/40: having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- C07C 231/02: from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
- C07D 207/02: with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D 295/18: by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 295/185: from aliphatic carboxylic acids
- C07C 2601/02: with a three-membered ring
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides caffeoylquinic acid derivatives and a method of preparing for the same, and also provides pharmaceutical compositions containing caffeoylquinic acid derivatives, and uses of caffeoylquinic acid derivatives in preparation of a medicament for the treatment or prophylaxis of virus diseases, in particular, uses of respiratory syncytial virus and hepatitis B virus, which has the characteristics of safety, high effectiveness and low toxicity.

## Claims

### Claim 1

A compound having Formula (1) or salts or hydrates thereof,
wherein R represents NH2, or any mono-substituted or di-substituted C1-C6 alkylamino group with straight chain or branched chain, or any substituted C3-C6 naphthenic amino group, or any substituted C1-C6 aromatic amino group, or pyrrolidinyl group or piperidyl group;
Q1, Q2, Q3, Q4 represent H or the following Formula (II) or a combination thereof, wherein Q1, Q2, Q3, Q4 cannot all represent H at the same time and Q1, Q2, Q3, Q4 cannot all represent Formula (II) at the same time.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R is chosen from the group comprising amino group, methylamino group, dimethylamino group, ethylamino group, isopropylamino group, pyrrolidinyl group, piperidyl group, anilino group, benzylamino group, para-tolylamino group, and cyclopropylamino group.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound the compound is chosen from the group comprising:

### Claim 4 (depends on 2)

The compound according to claim 2, wherein the compound the compound is chosen from the group comprising:

### Claim 5 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of at least one of compound according to claim 1 and pharmaceutically acceptable carriers or excipients.

### Claim 6 (depends on 2)

A pharmaceutical composition comprising a therapeutically effective amount of at least one of compound according to claim 2 and pharmaceutically acceptable carriers or excipients.

### Claim 7 (depends on 3)

A pharmaceutical composition comprising a therapeutically effective amount of at least one of compound according to claim 3 and pharmaceutically acceptable carriers or excipients.

### Claim 8 (depends on 4)

A pharmaceutical composition comprising a therapeutically effective amount of at least one of compound according to claim 4 and pharmaceutically acceptable carriers or excipients.

### Claim 9 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the carrier is chosen from the group comprising: tablet, capsule, pill, oral liquid preparation, granule, powder, injection, implant, and external preparation.

### Claim 10 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the carrier is chosen from the group comprising: tablet, capsule, pill, oral liquid preparation, granule, powder, injection, implant, and external preparation.

### Claim 11 (depends on 7)

The pharmaceutical composition according to claim 7, wherein the carrier is chosen from the group comprising: tablet, capsule, pill, oral liquid preparation, granule, powder, injection, implant, and external preparation.

### Claim 12 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the carrier is chosen from the group comprising: tablet, capsule, pill, oral liquid preparation, granule, powder, injection, implant, and external preparation.

### Claim 13 (depends on 1)

A method of preparing a compound having a formula according to claim 1, wherein the method comprises the steps of:
(1) reacting quinic acid of Formula 4 with R to obtain a compound of Formula 3:
(2) and then reacting Formula 3 with Formula II to obtain a compound of Formula I
wherein R represents NH2, or any mono-substituted or di-substituted C1-C6 alkylamino group with straight chain or branched chain, or any substituted C3-C6 naphthenic amino group, or any substituted C1-C6 aromatic amino group, or pyrrolidinyl group or piperidyl group.

### Claim 14 (depends on 2)

A method of preparing a compound having a formula according to claim 2, wherein the method comprises the steps of:
(1) reacting quinic acid of Formula 4 with R to obtain a compound of Formula 3:
(2) and then reacting Formula 3 with Formula II to obtain a compound of Formula I
wherein R represents NH2, or any mono-substituted or di-substituted C1-C6 alkylamino group with straight chain or branched chain, or any substituted C3-C6 naphthenic amino group, or any substituted C1-C6 aromatic amino group, or pyrrolidinyl group or piperidyl group.

### Claim 15 (depends on 3)

A method of preparing a compound having a formula according to claim 3, wherein the method comprises the steps of
(1) reacting quinic acid of Formula 4 with R to obtain a compound of Formula 3:
(2) and then reacting Formula 3 with Formula II to obtain a compound of Formula I
wherein R represents NH2, or any mono-substituted or di-substituted C1-C6 alkylamino group with straight chain or branched chain, or any substituted C3-C6 naphthenic amino group, or any substituted C1-C6 aromatic amino group, or pyrrolidinyl group or piperidyl group.

### Claim 16 (depends on 4)

A method of preparing a compound having a formula according to claim 4, wherein the method comprises the steps of:
(1) reacting quinic acid of Formula 4 with R to obtain a compound of Formula 3:
(2) and then reacting Formula 3 with Formula II to obtain a compound of Formula I
wherein R represents NH2, or any mono-substituted or di-substituted C1-C6 alkylamino group with straight chain or branched chain, or any substituted C3-C6 naphthenic amino group, or any substituted C1-C6 aromatic amino group, or pyrrolidinyl group or piperidyl group.

### Claim 17 (depends on 1)

A pharmaceutical composition for treatment of viral diseases comprising a therapeutically effective amount of at least one of compound according to claim 1 and pharmaceutically acceptable carriers or excipients.

### Claim 18 (depends on 2)

A pharmaceutical composition for treatment of viral diseases comprising a therapeutically effective amount of at least one of compound according to claim 2 and pharmaceutically acceptable carriers or excipients.

### Claim 19 (depends on 3)

A pharmaceutical composition for treatment of viral diseases comprising a therapeutically effective amount of at least one of compound according to claim 3 and pharmaceutically acceptable carriers or excipients.

### Claim 20 (depends on 17)

The composition according to claim 17, wherein the viruses are respiratory syncytial virus, AIDS virus, or hepatitis B virus.
